| 2026-09-17 |
Astellas Pharma Inc |
PADCEV™ (enfortumab vedotin) in Combination with Keytruda® (pembrolizumab) Receives Positive CHMP Opinion for the Treatment of Adults with Resectable Muscle-Invasive Bladder Cancer astellas.com ↗ |
| 2026-07-12 |
Astellas Pharma Inc |
U.S. FDA Approves PADCEV® plus Keytruda® as Neoadjuvant and Adjuvant Treatment for Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility astellas.com ↗ |
| 2026-07-10 |
Pfizer |
U.S. FDA Approves PADCEV® plus Keytruda® as Neoadjuvant and Adjuvant Treatment for Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility pfizer.com ↗ |
| 2026-07-10 |
Merck Sharp & Dohme LLC |
FDA Approves KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Each With Padcev® (enfortumab vedotin-ejfv), as Treatment Before and After Surgery for Adults With Muscle-Invasive Bladder Cancer (MIBC) merck.com ↗ |
| 2026-07-06 |
Astellas Pharma Inc |
China’s National Medical Products Administration Accepts Biologics License Application for PADCEV™ (enfortumab vedotin) plus Keytruda® (pembrolizumab) in Muscle-Invasive Bladder Cancer astellas.com ↗ |
| 2026-06-24 |
Merck Sharp & Dohme LLC |
European Commission Approves KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) as First PD-1 Inhibitor Plus Antibody-Drug Conjugate Regimen for Adults With Cisplatin-Ineligible Resectable Muscle-Invasive Bladder Cancer merck.com ↗ |
| 2026-06-23 |
Astellas Pharma Inc |
European Commission Approves PADCEV™ (enfortumab vedotin) in Combination with Keytruda® (pembrolizumab) as the First and Only Approved Perioperative Treatment Option for Cisplatin-Ineligible Patients with Resectable Muscle-Invasive Bladder Cancer astellas.com ↗ |
| 2026-05-22 |
Merck Sharp & Dohme LLC |
Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) as Perioperative Treatment for Adults With Cisplatin-Ineligible Resectable Muscle-Invasive Bladder Cancer merck.com ↗ |
| 2026-05-21 |
Astellas Pharma Inc |
PADCEV™ (enfortumab vedotin) in Combination with Keytruda® (pembrolizumab) Receives Positive CHMP Opinion for the Treatment of Patients with Resectable Muscle-Invasive Bladder Cancer who are Ineligible for Cisplatin-Based Chemotherapy astellas.com ↗ |
| 2026-05-14 |
Astellas Pharma Inc |
Astellas Submits Supplemental New Drug Application in Japan for PADCEV™ (enfortumab vedotin) plus Keytruda® (pembrolizumab) in Cisplatin-Eligible Patients with Muscle-Invasive Bladder Cancer astellas.com ↗ |
| 2026-04-20 |
Pfizer |
U.S. FDA Grants Priority Review to sBLA for PADCEV™ + Keytruda® as Perioperative Treatment for Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility pfizer.com ↗ |
| 2026-04-20 |
Merck Sharp & Dohme LLC |
FDA Grants Priority Review for KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Each with Padcev® (enfortumab vedotin-ejfv), for Cisplatin-Eligible Patients with Muscle-Invasive Bladder Cancer merck.com ↗ |
| 2026-04-20 |
Astellas Pharma Inc |
U.S. FDA Grants Priority Review to sBLA for PADCEV™ + Keytruda® as Perioperative Treatment for Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility astellas.com ↗ |
| 2026-03-22 |
Astellas Pharma Inc |
EMA Validates Type II Variation Application for PADCEV™ (enfortumab vedotin) plus Keytruda ® (pembrolizumab) in Cisplatin-Eligible Patients with Muscle-Invasive Bladder Cancer astellas.com ↗ |
| 2026-03-01 |
Astellas Pharma Inc |
PADCEV™ + Keytruda ® Cuts Risk of Recurrence or Death by Nearly 50% in Cisplatin-Eligible Muscle-Invasive Bladder Cancer astellas.com ↗ |
| 2026-02-27 |
Pfizer |
PADCEV™ + Keytruda® Cuts Risk of Recurrence or Death by Nearly 50% in Cisplatin-Eligible Muscle-Invasive Bladder Cancer pfizer.com ↗ |
| 2026-02-27 |
Merck Sharp & Dohme LLC |
KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) Reduced Risk of Event-Free Survival Events by 47% and Risk of Death by 35% for Cisplatin-Eligible Patients with Muscle-Invasive Bladder Cancer When Given Before and After Surgery merck.com ↗ |
| 2026-01-30 |
Astellas Pharma Inc |
Astellas Submits Supplemental New Drug Application in Japan for PADCEV™ (enfortumab vedotin) with Keytruda ® (pembrolizumab) for Certain Patients with Muscle-Invasive Bladder Cancer astellas.com ↗ |
| 2025-12-17 |
Pfizer |
PADCEV™ Plus Keytruda® Significantly Improves Survival for Patients with Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility pfizer.com ↗ |
| 2025-12-17 |
Merck Sharp & Dohme LLC |
KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) Significantly Improved Event-Free Survival, Overall Survival and Pathologic Complete Response Rates for Cisplatin-Eligible Patients with MIBC When Given Before and After Surgery merck.com ↗ |
| 2025-12-17 |
Astellas Pharma Inc |
PADCEV™ Plus Keytruda ® Significantly Improves Survival for Patients with Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility astellas.com ↗ |
| 2025-11-30 |
Astellas Pharma Inc |
European Medicines Agency Validates Type II Variation Application for PADCEV TM (enfortumab vedotin) with KEYTRUDA TM (pembrolizumab) for Certain Patients with Muscle-Invasive Bladder Cancer astellas.com ↗ |
| 2025-11-24 |
Astellas Pharma Inc |
U.S. FDA Approves PADCEV ® plus Keytruda ® for Certain Patients with Bladder Cancer astellas.com ↗ |
| 2025-11-21 |
Pfizer |
U.S. FDA Approves PADCEV® plus Keytruda® for Certain Patients with Bladder Cancer pfizer.com ↗ |
| 2025-11-21 |
Merck Sharp & Dohme LLC |
FDA Approves KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Each with Padcev® (enfortumab vedotin-ejfv), as Perioperative Treatment for Adults with Cisplatin-Ineligible Muscle-Invasive Bladder Cancer merck.com ↗ |
| 2025-10-23 |
Merck Sharp & Dohme LLC |
FDA Grants Priority Review for KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Each in Combination with Padcev® (enfortumab vedotin-ejfv), for Certain Patients with Muscle-Invasive Bladder Cancer merck.com ↗ |
| 2025-10-21 |
Astellas Pharma Inc |
PADCEV™ (enfortumab vedotin-ejfv) Plus KEYTRUDA ® (pembrolizumab) sBLA Granted FDA Priority Review for Treatment of Certain Patients with Muscle-Invasive Bladder Cancer astellas.com ↗ |
| 2025-10-19 |
Astellas Pharma Inc |
PADCEV™ Plus KEYTRUDA™, Given Before and After Surgery, Cuts the Risk of Recurrence, Progression or Death by 60% and the Risk of Death by 50% for Certain Patients with Bladder Cancer astellas.com ↗ |
| 2025-10-18 |
Pfizer |
PADCEV™ Plus KEYTRUDA™, Given Before and After Surgery, Cuts the Risk of Recurrence, Progression or Death by 60% and the Risk of Death by 50% for Certain Patients with Bladder Cancer pfizer.com ↗ |
| 2025-10-18 |
Merck Sharp & Dohme LLC |
KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) Reduced Risk of Event-Free Survival Events by 60% and Risk of Death by 50% for Certain Patients with Muscle-Invasive Bladder Cancer When Given Before and After Surgery merck.com ↗ |
| 2025-08-12 |
Pfizer |
PADCEV™ Plus KEYTRUDA™ Significantly Improves Survival for Certain Patients with Bladder Cancer When Given Before and After Surgery pfizer.com ↗ |
| 2025-08-12 |
Merck Sharp & Dohme LLC |
KEYTRUDA® (pembrolizumab) plus Padcev® (enfortumab vedotin-ejfv) Significantly Improved Event-Free and Overall Survival and Pathologic Complete Response Rate for Certain Patients with Muscle-Invasive Bladder Cancer When Given Before and After Surgery merck.com ↗ |
| 2025-08-12 |
Astellas Pharma Inc |
PADCEV TM Plus KEYTRUDA TM Significantly Improves Survival for Certain Patients with Bladder Cancer When Given Before and After Surgery astellas.com ↗ |
| 2025-02-12 |
Astellas Pharma Inc |
Pfizer and Astellas’ PADCEV ® (enfortumab vedotin-ejfv) plus KEYTRUDA ® (pembrolizumab) Shows Long-Term Efficacy in First Line Treatment of Locally Advanced or Metastatic Urothelial Cancer (la/mUC) astellas.com ↗ |
| 2025-02-10 |
Pfizer |
Pfizer and Astellas’ PADCEV® (enfortumab vedotin-ejfv) plus KEYTRUDA® (pembrolizumab) Shows Long-Term Efficacy in First-Line Treatment of Locally Advanced or Metastatic Urothelial Cancer (la/mUC) pfizer.com ↗ |
| 2025-01-08 |
Astellas Pharma Inc |
China’s National Medical Products Administration (NMPA) Approves PADCEV TM in combination with KEYTRUDA ® (pembrolizumab) for the Treatment of Advanced Bladder Cancer astellas.com ↗ |
| 2024-09-24 |
Astellas Pharma Inc |
Japan’s Ministry of Health, Labour and Welfare Approves PADCEV TM (enfortumab vedotin) with KEYTRUDA ® (pembrolizumab) for First-Line Treatment of Radically Unresectable Urothelial Carcinoma astellas.com ↗ |
| 2024-09-03 |
Merck Sharp & Dohme LLC |
European Commission Approves Merck’s KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) as First-Line Treatment of Unresectable or Metastatic Urothelial Carcinoma in Adults merck.com ↗ |
| 2024-08-28 |
Astellas Pharma Inc |
European Commission Approves Astellas’ PADCEV TM (enfortumab vedotin) in Combination with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Advanced Urothelial Cancer astellas.com ↗ |
| 2024-08-20 |
Astellas Pharma Inc |
China’s National Medical Products Administration (NMPA) Approves PADCEV TM (enfortumab vedotin) for Treatment of Locally Advanced or Metastatic Urothelial Cancer astellas.com ↗ |
| 2024-07-29 |
Astellas Pharma Inc |
Astellas Receives Positive CHMP Opinion for PADCEV TM (enfortumab vedotin) in combination with KEYTRUDA ® (pembrolizumab) for First-Line Treatment of Advanced Bladder Cancer astellas.com ↗ |
| 2024-07-26 |
Merck Sharp & Dohme LLC |
Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) as First-Line Treatment for Patients With Unresectable or Metastatic Urothelial Carcinoma merck.com ↗ |
| 2024-03-28 |
Astellas Pharma Inc |
China’s National Medical Products Administration Accepts Astellas and Pfizer’s Supplemental Biologics License Application for enfortumab vedotin with KEYTRUDA ® (pembrolizumab) for First-Line Treatment of Advanced Bladder Cancer astellas.com ↗ |
| 2024-02-15 |
Astellas Pharma Inc |
PADCEV TM (enfortumab vedotin (genetical recombination)) with KEYTRUDA ® (pembrolizumab (genetical recombination)) Granted Priority Review by Japan’s Ministry of Health, Labour and Welfare for First-Line Treatment of Advanced Bladder Cancer astellas.com ↗ |
| 2024-01-31 |
Astellas Pharma Inc |
Astellas Submits Supplemental New Drug Application in Japan for PADCEV TM (enfortumab vedotin (genetical recombination) with KEYTRUDA ® (pembrolizumab (genetical recombination)) for First-Line Treatment of Advanced Bladder Cancer astellas.com ↗ |
| 2024-01-26 |
Pfizer |
European Medicines Agency Validates Type II Variation Application for PADCEV® (enfortumab vedotin) with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Advanced Bladder Cancer pfizer.com ↗ |
| 2024-01-26 |
Astellas Pharma Inc |
European Medicines Agency Validates Type II Variation Application for PADCEV TM (enfortumab vedotin) with KEYTRUDA ® (pembrolizumab) for First-Line Treatment of Advanced Bladder Cancer astellas.com ↗ |
| 2023-12-15 |
Pfizer |
PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) Approved by FDA as the First and Only ADC Plus PD-1 to Treat Advanced Bladder Cancer pfizer.com ↗ |
| 2023-12-15 |
Merck Sharp & Dohme LLC |
FDA Approves Expanded Indication for KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) for the First-Line Treatment of Adult Patients With Locally Advanced or Metastatic Urothelial Cancer merck.com ↗ |
| 2023-12-15 |
Astellas Pharma Inc |
PADCEV ® (enfortumab vedotin-ejfv) with KEYTRUDA ® (pembrolizumab) Approved by FDA as the First and Only ADC Plus PD-1 to Treat Advanced Bladder Cancer astellas.com ↗ |
| 2023-11-30 |
Merck Sharp & Dohme LLC |
FDA Grants Priority Review to Merck’s Application for KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) for the First-Line Treatment of Patients With Locally Advanced or Metastatic Urothelial Cancer merck.com ↗ |
| 2023-11-30 |
Astellas Pharma Inc |
FDA Grants Priority Review for Supplemental Biologics License Application (sBLA) of PADCEV ® (enfortumab vedotin-ejfv) with KEYTRUDA ® (pembrolizumab) for First-Line Treatment of Advanced Bladder Cancer astellas.com ↗ |
| 2023-10-22 |
Merck Sharp & Dohme LLC |
KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) Reduced Risk of Death by More Than Half Versus Chemotherapy in Patients With Previously Untreated Locally Advanced or Metastatic Urothelial Cancer merck.com ↗ |
| 2023-10-22 |
Astellas Pharma Inc |
Groundbreaking EV-302 Trial Significantly Extends Overall Survival and Progression-Free Survival in Patients Treated with PADCEV ® (enfortumab vedotin-ejfv) and KEYTRUDA ® (pembrolizumab) in First-Line Advanced Bladder Cancer astellas.com ↗ |
| 2023-09-22 |
Astellas Pharma Inc |
PADCEV ® (enfortumab vedotin-ejfv) and KEYTRUDA ® (pembrolizumab) Significantly Improve Overall Survival and Progression-Free Survival in Patients With Previously Untreated Advanced Bladder Cancer in Pivotal Phase 3 EV-302 Trial astellas.com ↗ |
| 2023-04-03 |
Merck Sharp & Dohme LLC |
FDA Approves Merck’s KEYTRUDA® (pembrolizumab) in Combination With Padcev® (enfortumab vedotin-ejfv) for First-Line Treatment of Certain Patients With Locally Advanced or Metastatic Urothelial Cancer merck.com ↗ |
| 2023-04-03 |
Astellas Pharma Inc |
FDA Grants Accelerated Approval for PADCEV ® (enfortumab vedotin-ejfv) with KEYTRUDA ® (pembrolizumab) for First-Line Treatment of Locally Advanced or Metastatic Urothelial Cancer astellas.com ↗ |
| 2023-03-09 |
Astellas Pharma Inc |
Astellas and Seagen Announce China’s National Medical Products Administration Accepts Biologics License Application for Enfortumab Vedotin in Certain Patients with Locally Advanced or Metastatic Urothelial Cancer astellas.com ↗ |
| 2022-12-20 |
Merck Sharp & Dohme LLC |
Astellas, Seagen and Merck Announce FDA Acceptance of Supplemental Biologics License Applications for PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) for the First-Line Treatment of Certain Patients With Locally Advanced or Metastatic Urothelial Cancer merck.com ↗ |
| 2022-12-20 |
Astellas Pharma Inc |
Astellas, Seagen and Merck Announce FDA Acceptance of sBLA for PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) for the First-Line Treatment of Certain Patients With Locally Advanced or Metastatic Urothelial Cancer astellas.com ↗ |
| 2022-09-12 |
Merck Sharp & Dohme LLC |
Seagen, Astellas and Merck Announce Results of Clinical Trial Investigating PADCEV® (enfortumab vedotin-ejfv) With KEYTRUDA® (pembrolizumab) and PADCEV as Monotherapy in First-Line Advanced Urothelial Cancer merck.com ↗ |
| 2022-09-12 |
Astellas Pharma Inc |
Astellas, Seagen and Merck Announce Results of Clinical Trial Investigating PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) and PADCEV as Monotherapy in First-Line Advanced Urothelial Cancer astellas.com ↗ |
| 2022-07-26 |
Astellas Pharma Inc |
Astellas and Seagen Announce Positive Topline Results For PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) as First-Line Treatment for Advanced Urothelial Cancer astellas.com ↗ |
| 2022-04-13 |
Astellas Pharma Inc |
European Commission Approves PADCEV™ (enfortumab vedotin) for Locally Advanced or Metastatic Urothelial Cancer astellas.com ↗ |
| 2022-02-28 |
Astellas Pharma Inc |
Astellas and Seagen Announce CHMP Confirms Positive Opinion for PADCEV™ (enfortumab vedotin) in Locally Advanced or Metastatic Urothelial Cancer astellas.com ↗ |
| 2022-02-14 |
Astellas Pharma Inc |
Astellas and Seagen Announce Initial Results of PADCEV® (enfortumab vedotin-ejfv) in Patients with Muscle-Invasive Bladder Cancer Not Eligible for Cisplatin Chemotherapy astellas.com ↗ |
| 2021-12-18 |
Astellas Pharma Inc |
FDA Grants Accelerated Approval to Astellas’ and Seattle Genetics’ PADCEV™ (enfortumab vedotin-ejfv) for People with Locally Advanced or Metastatic Urothelial Cancer, the Most Common Type of Bladder Cancer astellas.com ↗ |
| 2021-12-17 |
Astellas Pharma Inc |
Astellas and Seagen Receive Positive CHMP Opinion for PADCEV™ (enfortumab vedotin) in Locally Advanced or Metastatic Urothelial Cancer astellas.com ↗ |
| 2021-10-12 |
Astellas Pharma Inc |
Astellas and Seagen Complete Enrollment in EV-103 Trial Cohort K Combining PADCEV® (enfortumab vedotin-ejfv) with Pembrolizumab as First-Line Treatment for Advanced Urothelial Cancer astellas.com ↗ |
| 2021-09-27 |
Astellas Pharma Inc |
Japan’s MHLW Approves PADCEV® (enfortumab vedotin) for Advanced Urothelial Cancer astellas.com ↗ |
| 2021-07-09 |
Astellas Pharma Inc |
U.S. FDA Grants Regular Approval and Expands Indication for PADCEV® (enfortumab vedotin-ejfv) for Patients with Locally Advanced or Metastatic Urothelial Cancer astellas.com ↗ |
| 2021-05-19 |
Astellas Pharma Inc |
Astellas and Seagen Announce Updated Results from Two Trials of PADCEV® (enfortumab vedotin-ejfv) in Patients with Locally Advanced or Metastatic Urothelial Cancer Not Eligible for Cisplatin Chemotherapy astellas.com ↗ |
| 2021-05-14 |
Astellas Pharma Inc |
Japan’s Ministry of Health, Labour and Welfare Grants Priority Review for Enfortumab Vedotin New Drug Application astellas.com ↗ |
| 2021-04-19 |
Astellas Pharma Inc |
Astellas and Seagen Announce U.S. FDA Acceptance of Two Supplemental Biologics License Applications for PADCEV® (enfortumab vedotin-ejfv) in Locally Advanced or Metastatic Urothelial Cancer astellas.com ↗ |
| 2021-03-26 |
Astellas Pharma Inc |
European Medicines Agency Accepts Marketing Authorization Application for Enfortumab Vedotin astellas.com ↗ |
| 2021-03-11 |
Astellas Pharma Inc |
Astellas Submits New Drug Application for Enfortumab Vedotin in Japan astellas.com ↗ |
| 2021-02-18 |
Astellas Pharma Inc |
Astellas and Seagen Announce Submission of Two Supplemental Biologics License Applications to the U.S. FDA for PADCEV® (enfortumab vedotin-ejfv) in Locally Advanced or Metastatic Urothelial Cancer astellas.com ↗ |
| 2021-02-12 |
Astellas Pharma Inc |
Astellas and Seagen Announce Presentation of Results from PADCEV® (enfortumab vedotin-ejfv) Pivotal Trial in Patients with Previously Treated Advanced Urothelial Cancer Who Were Ineligible for Cisplatin Chemotherapy astellas.com ↗ |
| 2021-02-12 |
Astellas Pharma Inc |
Astellas and Seagen Announce Phase 3 Trial Results Demonstrating Survival Advantage of PADCEV® (enfortumab vedotin-ejfv) in Patients with Previously Treated Advanced Urothelial Cancer astellas.com ↗ |
| 2020-10-12 |
Astellas Pharma Inc |
Astellas and Seagen Announce Positive Topline Results from Second Cohort of Patients in Phase 2 Pivotal Trial of PADCEV® (enfortumab vedotin-ejfv) in Advanced Urothelial Cancer astellas.com ↗ |
| 2020-09-18 |
Astellas Pharma Inc |
Astellas and Seattle Genetics Announce PADCEV® (enfortumab vedotin-ejfv) Significantly Improved Overall Survival in Phase 3 Trial in Previously Treated Locally Advanced or Metastatic Urothelial Cancer astellas.com ↗ |
| 2020-02-19 |
Astellas Pharma Inc |
Astellas and Seattle Genetics Receive FDA Breakthrough Therapy Designation for PADCEV™ (enfortumab vedotin-ejfv) in Combination with Pembrolizumab in First-Line Advanced Bladder Cancer astellas.com ↗ |
| 2020-02-10 |
Astellas Pharma Inc |
Seattle Genetics and Astellas Announce Updated Results from Phase 1b/2 Trial of PADCEV™ (enfortumab vedotin-ejfv) in Combination with Immune Therapy Pembrolizumab as Investigational First-Line Treatment for Advanced Bladder Cancer astellas.com ↗ |
| 2019-12-03 |
Astellas Pharma Inc |
Seattle Genetics and Astellas Announce Clinical Trial Collaboration with Merck to Evaluate Enfortumab Vedotin in Combination with KEYTRUDA® (pembrolizumab) in Patients with Metastatic Urothelial Cancer astellas.com ↗ |
| 2019-09-30 |
Astellas Pharma Inc |
Seattle Genetics and Astellas Announce Results from Phase 1 Trial of Investigational Agent Enfortumab Vedotin in Combination with Immune Therapy Pembrolizumab as First-Line Treatment for Advanced Bladder Cancer astellas.com ↗ |
| 2019-09-17 |
Astellas Pharma Inc |
Seattle Genetics and Astellas Announce US FDA Grants Priority Review for Enfortumab Vedotin Biologics License Application in Locally Advanced or Metastatic Urothelial Cancer astellas.com ↗ |
| 2019-07-17 |
Astellas Pharma Inc |
Astellas and Seattle Genetics Announce Submission of Biologics License Application to FDA for Enfortumab Vedotin for Patients with Locally Advanced or Metastatic Urothelial Cancer astellas.com ↗ |
| 2019-06-04 |
Astellas Pharma Inc |
Astellas and Seattle Genetics Announce Antibody-Drug Conjugate Enfortumab Vedotin Produced Tumor Response Rate of 44 Percent in Patients with Most Common Type of Advanced Urothelial (Bladder) Cancer astellas.com ↗ |
| 2019-03-28 |
Astellas Pharma Inc |
Seattle Genetics and Astellas Announce Positive Topline Results from Pivotal Trial of Enfortumab Vedotin in Locally Advanced or Metastatic Urothelial Cancer - Companies Plan to Submit Biologics License Application Later This Year – astellas.com ↗ |
| 2018-07-10 |
Astellas Pharma Inc |
Seattle Genetics and Astellas Announce Progress in Enfortumab Vedotin Urothelial Cancer Clinical Development Program astellas.com ↗ |
| 2018-06-04 |
Astellas Pharma Inc |
Astellas and Seattle Genetics Present at ASCO 2018 on Enfortumab Vedotin in Patients with Locally Advanced or Metastatic Urothelial Cancer Previously Treated with Checkpoint Inhibitor Therapy astellas.com ↗ |
| 2018-03-27 |
Astellas Pharma Inc |
Astellas and Seattle Genetics Receive FDA Breakthrough Therapy Designation for Enfortumab Vedotin in Locally Advanced or Metastatic Urothelial Cancer astellas.com ↗ |
| 2017-10-11 |
Astellas Pharma Inc |
Astellas and Seattle Genetics Initiate Pivotal Trial of Enfortumab Vedotin for Patients with Locally Advanced or Metastatic Urothelial Cancer astellas.com ↗ |
|